Crinetics stock nearly doubled Tuesday after Vertex pledged $10 billion to buy the endocrinology-focused biotech.
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Licensing
Crinetics stock nearly doubled early Tuesday after Vertex Pharmaceuticals pledged $10 billion to buy the endocrinology-focused biotech company. The smaller company sells Palsonify, a treatment for acromegaly, and is working on a treatment for congenital adrenal hyperplasia, or CAH, called atumelnant. The Crinetics Pharmaceuticals' (CRNX) drugs are daily pills and would add an estimated $5 billion in peak sales to…
Vertex Pharmaceuticals (VRTX) fell about 2.3% after hours on Monday following a deal to acquire endocrine‑focused drugmaker…
Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid…
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder,…
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and…
Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stage CAH candidate atumelnant to…
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire | Vertex Pharmaceuticals has struck a $10…
